These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 16542875)

  • 21. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
    Xing Z; Charters TJ
    Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route.
    Gupta A; Geetha N; Mani J; Upadhyay P; Katoch VM; Natrajan M; Gupta UD; Bhaskar S
    Infect Immun; 2009 Jan; 77(1):223-31. PubMed ID: 18981249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New vaccines for the prevention of tuberculosis.
    von Reyn CF; Vuola JM
    Clin Infect Dis; 2002 Aug; 35(4):465-74. PubMed ID: 12145732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is a new tuberculosis vaccine necessary and feasible? A Cuban opinion.
    Sierra VG
    Tuberculosis (Edinb); 2006; 86(3-4):169-78. PubMed ID: 16677860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice.
    Wang LM; Bai YL; Shi CH; Gao H; Xue Y; Jiang H; Xu ZK
    APMIS; 2008 Dec; 116(12):1071-81. PubMed ID: 19133010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Animal models for experimental tuberculosis.
    Smith D; Wiegeshaus E; Balasubramanian V
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S68-70. PubMed ID: 11010825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune responses to tuberculosis in developing countries: implications for new vaccines.
    Rook GA; Dheda K; Zumla A
    Nat Rev Immunol; 2005 Aug; 5(8):661-7. PubMed ID: 16056257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvants in tuberculosis vaccine development.
    Moreno-Mendieta SA; Rocha-Zavaleta L; Rodriguez-Sanoja R
    FEMS Immunol Med Microbiol; 2010 Feb; 58(1):75-84. PubMed ID: 20002177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice.
    Solans L; Uranga S; Aguilo N; Arnal C; Gomez AB; Monzon M; Badiola JJ; Gicquel B; Martin C
    Vaccine; 2014 Sep; 32(40):5192-7. PubMed ID: 25066740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration.
    Giri PK; Verma I; Khuller GK
    FEMS Immunol Med Microbiol; 2006 Jul; 47(2):233-41. PubMed ID: 16831210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tuberculosis vaccines: the past, present and future.
    Wang J; Xing Z
    Expert Rev Vaccines; 2002 Oct; 1(3):341-54. PubMed ID: 12901573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex.
    Collins DM
    Immunol Cell Biol; 2000 Aug; 78(4):342-8. PubMed ID: 10947858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of a Mycobacterium tuberculosis DeltaRD1 DeltapanCD double deletion mutant in a neonatal calf aerosol M. bovis challenge model: comparisons to responses elicited by M. bovis bacille Calmette Guerin.
    Waters WR; Palmer MV; Nonnecke BJ; Thacker TC; Scherer CF; Estes DM; Jacobs WR; Glatman-Freedman A; Larsen MH
    Vaccine; 2007 Nov; 25(45):7832-40. PubMed ID: 17931755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.
    Wang QL; Pan Q; Ma Y; Wang K; Sun P; Liu S; Zhang XL
    Vaccine; 2009 Nov; 27(48):6712-22. PubMed ID: 19733584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant.
    Senaratne RH; Mougous JD; Reader JR; Williams SJ; Zhang T; Bertozzi CR; Riley LW
    J Med Microbiol; 2007 Apr; 56(Pt 4):454-458. PubMed ID: 17374883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of BCG vaccine strain on the immune response and protection against tuberculosis.
    Ritz N; Hanekom WA; Robins-Browne R; Britton WJ; Curtis N
    FEMS Microbiol Rev; 2008 Aug; 32(5):821-41. PubMed ID: 18616602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study of a role of artificial mycobacterial particles in the realization of immunological processes in experimental animal tuberculosis].
    Azaev MSh; Lebedev LR; Kuz'micheva GA; Tumanov IuV; Donchenko NA; Tat'kov SI; Nosareva OV; Il'ichev AA
    Probl Tuberk Bolezn Legk; 2007; (2):38-42. PubMed ID: 17419334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current tuberculosis vaccine development.
    Young DB
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S254-6. PubMed ID: 10875794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant Mycobacterium bovis BCG.
    Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
    Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.